Wanbury Ltd - Sertraline Form II approval received from ANVISA, BRAZIL

Wanbury Limited (WL) has received Sertraline Form II approval from ANVISA, BRAZIL. This is in addition to Sertraline hydrochloride Form 1 approval that Wanbury already has. WL currently hold 75% market share for sertraline in Brazil's market. Approval for Form II, will help in further consolidation company's share of business.

WL has received approval from one of the largest customer for a special grade of metformin · DC grade with potential business opportunity to be estimated around Rupees 15 crore per annum. Both the API manufacturing sites i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations.

Shares of Wanbury Limited was last trading in BSE at Rs. 245.35 as compared to the previous close of Rs. 243.85. The total number of shares traded during the day was 255 in over 12 trades.

The stock hit an intraday high of Rs. 247.95 and intraday low of 242.35. The net turnover during the day was Rs. 62530.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Pharmaceuticals ANVISA Brazil SertralineFormIIApproval